Frontlight ResearchEarly access
Taking people in United StatesNo phase
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
Key facts
- Who runs it
- M.D. Anderson Cancer Center
- Where
- Houston, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 11 Sept 2024
- Expected to end
- 31 Mar 2028
- Type of study
- Observational
- Record updated
- 6 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- The criteria are:
- Patients aged 18 years and above
- English (conversational level) speaking, with the ability to give informed consent
- Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy
Who cannot take part
- Acutely life-threatening or worsening cancer
- Hearing impairment functionally limiting participation in verbal interview
Where in United States
- MD Anderson Cancer CenterHouston, United StatesContact: Y. Jeff Li, MDTaking people
About the trial
What the trial wants to find out
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 6 October 2026